Kinarus KOL Webcast
27 June 2022
Disclaimer
This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
issued by Kinarus Therapeutics Holding AG. Kinarus Therapeutics Holding AG makes no representation (either express or implied) that
information and opinions expressed in this presentation are accurate, complete or up to date. Kinarus Therapeutics Holdings AG disclaims, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information contained in this presentation.
This presentation expressly or implicitly contains certain forward-looking statements concerning Kinarus Therapeutics Holdings AG and its business. Certain of these forward-looking statements can be identified by the use of forward-looking terminology or by discussions of strategy, plans or intentions. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Kinarus Therapeutics Holdings AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that any of the research and/or development projects described will succeed or that any news products or indications will be brought to market. Similarly, there can be no guarantee that Kinarus Therapeutics Holdings or any future product or indication will achieve any particular level of revenue. In particular, management's expectations could be affected by, among other things, uncertainties involved in the development
of new pharmaceutical products, including unexpected preclinical and clinical trial results; unexpected regulatory actions or delays or
government regulation generally; the Kinarus Therapeutics Holding AG's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Kinarus Therapeutics Holding AG is providing the information in this presentation as of the date of the publication and does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
2
Overview
- Kinarus Therapeutics Holding AG
- Headquarters: Basel, Switzerland
- Six Swiss Exchange: KNRS
- Shares outstanding: 1.07 BN
- Cash: CHF8.8 M*
- Debt: CHF7.8 M*
- Market cap: CHF36.4 M
- Avg daily trading volume: 4.2 M
- Major Shareholders
- Management & Board: 20.3%
- Public free float: 52.4%
*as of 31 Dec 2021
- Phase 2 asset: KIN001
- New drug combination
- Pamapimod in-licensed from Roche (Phase 2)
- Pioglitazone (marketed generic)
- Combo is synergistic & addresses issues
- Indications for value creation
- AMD
- IPF
- Covid-19
- Strategy
- In-licenseclinical-stagedrug-candidates
- Develop to proof of concept
- Exit
3
Experienced Leadership
We are drug developers
Dr. Alexander Bausch | Subhasis Roy | |||||||
Chief Executive Officer | Interim CFO | |||||||
Dr. Matthew Wright | Claudia Berger | |||||||
Chief Operations Officer | Chief Clinical Dev. Officer | |||||||
Head of Research | ||||||||
Dr. Thierry Fumeaux | ||||||||
Chief Medical Officer |
- Direct know-how and in-depth expertise with Kinarus' therapeutic targets and disease indications
- Established relationships with leading experts in clinical development
4
Scientific and Clinical Advisors
Age-Related Macular Degeneration (AMD)
Dr. Viktor Boerlin
Chief Medical Advisor
Prof. Dr. Hendrik Scholl
Director, Institute of Molecular and Clinical
Ophthalmology Basel (IOB)
Professor and Chairman of the Department
of Ophthalmology, University of Basel,
Switzerland
Chair of the European Vision Institute EEIG, the European Alliance for the Promotion of Vision Research and Ophthalmology
Prof. Dr. Christian Prünte
Head of Clinical Trials Platform
Institute of Molecular and Clinical
Ophthalmology Basel (IOB)
Professor and Clinical Chairman of
the Department of Ophthalmology,
University of Basel, Switzerland
Dr. Bianca Gerendas
Managing Director
Vienna Read Center, Vienna, Austria
Associate Director,
Christian Doppler Laboratory
of Ophthalmic Image Analysis
Idiopathic Pulmonary Fibrosis (IPF)
Katrin Hostettler MD, PhD
Head of Dept., Pulmonology
University Hospital Basel
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Kinarus Therapeutics Holding AG published this content on 27 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 June 2022 10:53:05 UTC.